N Sarita Shah, Cissy Kityo, Michael D Hughes, Caitlyn McCarthy, Carole Wallis, Mina Hosseinipour, Deborah Langat, Mulinda Nyirenda, Mohammed Rassool, Rodney Dawson, Yvetot Joseph, Fatma Some, Rosie Mngqbisa, Pamela Grace Mukwekwerere, Elizabeth Woolley, Catherine Godfrey, Yukari C Manabe, John W Mellors, Charles Flexner, Gary Maartens
BACKGROUND: Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50 mg dose of dolutegravir (TLD + 50) is required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on the effectiveness of TLD + 50 in individuals with TB/HIV. METHODS: Prospective, observational cohort study at 12 sites in Haiti, Kenya, Malawi, South Africa, Uganda, Zimbabwe...
May 13, 2024: Clinical Infectious Diseases